Radius Health Inc. (NASDAQ:RDUS) announced a worldwide collaboration with Novartis AG NVS for the evaluation of the efficacy and safety of combining its RAD1901 with Novartis’ LEE011 (ribociclib).
Under the collaboration agreement, Radius and Novartis will provide compound material and resources for the studies to be conducted and will share third party out-of-pocket research and development expenses. The agreement is non-exclusive. The companies also plan to conduct pre-clinical studies on the combination of RAD1901 and BYL719 (alpelisib).
We note that RAD1901 is currently in an open-label, two-part, dose-escalation, phase I study in postmenopausal women who are suffering from advanced estrogen receptor positive and HER2 negative breast cancer.
Additionally, Radius is conducting a phase IIb study on the candidate for the treatment of vasomotor symptoms.
Meanwhile, we expect investor focus to remain on the company’s regulatory progress with its lead pipeline candidate, abaloparatide. Abaloparatide subcutaneous (SC) is currently under regulatory review in the EU for the treatment of osteoporosis in postmenopausal women. Radius is looking for a commercialization partner for abaloparatide and intends to file for FDA approval by the end of this quarter.
Radius is also looking to develop a short wear time transdermal patch of abaloparatide a human replicative study was initiated in Dec 2015 with data read-out expected in mid-2016.
Radius Health Equity Analysis
Radius Health Inc. (NASDAQ:RDUS) opened trading today as $33.21 and is trading in the range of 32.25-37.00 today. Radius Health’s current market cap stands at $1.43 billion.
Radius Health mean target price is $70.60 according to First Call. This presents a solid upside to the current price of the equity. The Mean Recommendation sits at 1.7
The most recent analyst actions consisted of JP Morgan initiating the stock on October 2nd
The current quarter EPS consensus estimate is -0.64. Radius Health reported actual earnings last quarter of -0.68 which beats the -0.57 consensus estimate, a -19.30% surprise.
Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. The companys lead product comprises abaloparatide SC (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein that is in Phase III clinical development for use in the reduction of fractures in postmenopausal osteoporosis; and Abaloparatide-TD, a line extension of abaloparatide-SC in the form of a transdermal patch that has completed Phase II clinical trial, which is used to increase bone mineral density. It is also developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer and other estrogen receptor mediated oncology applications, as well as in Phase II proof of concept study for the treatment of vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer or other conditions. The company has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai Co. Ltd; and Lonza Group Ltd. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.